CERVOMED INC (CRVO) Fundamental Analysis & Valuation

NASDAQ:CRVO • US15713L1098

Current stock price

3.98 USD
-0.01 (-0.25%)
Last:

This CRVO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CRVO Profitability Analysis

1.1 Basic Checks

  • In the past year CRVO has reported negative net income.
  • CRVO had a negative operating cash flow in the past year.
  • In the past 5 years CRVO always reported negative net income.
  • In the past 5 years CRVO always reported negative operating cash flow.
CRVO Yearly Net Income VS EBIT VS OCF VS FCFCRVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • CRVO has a worse Return On Assets (-117.86%) than 79.69% of its industry peers.
  • The Return On Equity of CRVO (-147.98%) is worse than 63.06% of its industry peers.
Industry RankSector Rank
ROA -117.86%
ROE -147.98%
ROIC N/A
ROA(3y)-59.15%
ROA(5y)-62%
ROE(3y)-72.99%
ROE(5y)-73.02%
ROIC(3y)N/A
ROIC(5y)N/A
CRVO Yearly ROA, ROE, ROICCRVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVO Yearly Profit, Operating, Gross MarginsCRVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CRVO Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CRVO has more shares outstanding
  • Compared to 5 years ago, CRVO has more shares outstanding
  • CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRVO Yearly Shares OutstandingCRVO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
CRVO Yearly Total Debt VS Total AssetsCRVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • CRVO has an Altman-Z score of -4.18. This is a bad value and indicates that CRVO is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -4.18, CRVO is not doing good in the industry: 61.12% of the companies in the same industry are doing better.
  • CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.18
ROIC/WACCN/A
WACCN/A
CRVO Yearly LT Debt VS Equity VS FCFCRVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • CRVO has a Current Ratio of 4.91. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.
  • CRVO's Current ratio of 4.91 is in line compared to the rest of the industry. CRVO outperforms 54.16% of its industry peers.
  • CRVO has a Quick Ratio of 4.91. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.
  • CRVO has a Quick ratio (4.91) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.91
Quick Ratio 4.91
CRVO Yearly Current Assets VS Current LiabilitesCRVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CRVO Growth Analysis

3.1 Past

  • CRVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.80%.
  • The Revenue for CRVO has decreased by -58.86% in the past year. This is quite bad
EPS 1Y (TTM)-46.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)-58.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.58%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.69% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 93.70% on average over the next years. This is a very strong growth
EPS Next Y16.88%
EPS Next 2Y17.52%
EPS Next 3Y12.84%
EPS Next 5Y9.69%
Revenue Next Year-98.76%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y93.7%

3.3 Evolution

CRVO Yearly Revenue VS EstimatesCRVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
CRVO Yearly EPS VS EstimatesCRVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

0

4. CRVO Valuation Analysis

4.1 Price/Earnings Ratio

  • CRVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVO Price Earnings VS Forward Price EarningsCRVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVO Per share dataCRVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CRVO's earnings are expected to grow with 12.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.52%
EPS Next 3Y12.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRVO Dividend Analysis

5.1 Amount

  • No dividends for CRVO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRVO Fundamentals: All Metrics, Ratios and Statistics

CERVOMED INC

NASDAQ:CRVO (4/17/2026, 8:03:56 PM)

3.98

-0.01 (-0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-11
Inst Owners24.13%
Inst Owner Change-1.28%
Ins Owners24.01%
Ins Owner Change2.01%
Market Cap36.85M
Revenue(TTM)4.01M
Net Income(TTM)-26.97M
Analysts81.43
Price Target22.59 (467.59%)
Short Float %4.99%
Short Ratio3.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.49%
Min EPS beat(2)-20.3%
Max EPS beat(2)-6.67%
EPS beat(4)1
Avg EPS beat(4)-4.8%
Min EPS beat(4)-20.3%
Max EPS beat(4)16.71%
EPS beat(8)2
Avg EPS beat(8)-8%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-88.31%
Min Revenue beat(2)-98.95%
Max Revenue beat(2)-77.68%
Revenue beat(4)1
Avg Revenue beat(4)-42.01%
Min Revenue beat(4)-98.95%
Max Revenue beat(4)9.17%
Revenue beat(8)4
Avg Revenue beat(8)-8.46%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.27%
PT rev (3m)-1.27%
EPS NQ rev (1m)-21.12%
EPS NQ rev (3m)-38.79%
EPS NY rev (1m)-28.26%
EPS NY rev (3m)-28.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-65.91%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-93.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.2
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 2.02
EV/EBITDA N/A
EPS(TTM)-2.98
EYN/A
EPS(NY)-2.48
Fwd EYN/A
FCF(TTM)-2.53
FCFYN/A
OCF(TTM)-2.53
OCFYN/A
SpS0.43
BVpS1.97
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -117.86%
ROE -147.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.15%
ROA(5y)-62%
ROE(3y)-72.99%
ROE(5y)-73.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.91
Quick Ratio 4.91
Altman-Z -4.18
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y16.88%
EPS Next 2Y17.52%
EPS Next 3Y12.84%
EPS Next 5Y9.69%
Revenue 1Y (TTM)-58.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.58%
Revenue Next Year-98.76%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y93.7%
EBIT growth 1Y-55.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-123.32%
EBIT Next 3Y-39.4%
EBIT Next 5Y-51.22%
FCF growth 1Y-41.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.86%
OCF growth 3YN/A
OCF growth 5YN/A

CERVOMED INC / CRVO Fundamental Analysis FAQ

What is the fundamental rating for CRVO stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRVO.


Can you provide the valuation status for CERVOMED INC?

ChartMill assigns a valuation rating of 0 / 10 to CERVOMED INC (CRVO). This can be considered as Overvalued.


How profitable is CERVOMED INC (CRVO) stock?

CERVOMED INC (CRVO) has a profitability rating of 0 / 10.